Anemia treatment in the pre-ESRD period and associated mortality in elderly patients

American Journal of Kidney Diseases

Volumn 40, Issue 6, 2002, Pages 1153-1161

  Xue, Jay L ^a   St Peter, Wendy L ^a   Ebben, James P ^a   Everson, Susan E ^a   Collins, Allan J ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Anemia; Epoetin; Hematocrit; Mortality; Pre end stage renal disease (pre ESRD)

Indexed keywords

ALBUMIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK ASSESSMENT; SURVIVAL RATE;

EID: 0036895429     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.36861     Document Type: Article

References (31)

1. Collins AJ, Ma J, Constantini E, Everson S: Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993. J Am Soc Nephrol 9:2108-2117, 1998
2. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 13:1642-1644, 1998
3. Ma J, Ebben J, Xia H, Collins A: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
4. Lim VS, DeGowin RL, Zavala D, et al: Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110: 108-114, 1989
5. Clyne N, Ekholm J, Jogestrand T, Lins LE, Pehrsson SK: Effects of exercise training in predialytic uremic patients. Nephron 59:84-89, 1991
6. Revicki DA, Brown RE, Feeny DH, et al: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554, 1995
7. Fink J, Blahut S, Reddy M, Light P: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37:348-355, 2001
8. SAS Institute Inc: SAS/STAT® User's Guide. Cary, NC, SAS Institute Inc, 1999
9. Goldwasser P, Mittman N, Antignani A, et al: Predictors of mortality in hemodialysis patients. J Am Soc Nephrol 3:1613-1622, 1993
10. Owen W, Lew N, Liu Y, Lowrie E, Lazarus M: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001-1006, 1993
11. Avram MM, Goldwasser P, Erroa M, Fein PA: Predictors of survival in continuous ambulatory peritoneal dialysis patients: The importance of prealbumin and other nutritional and metabolic markers. Am J Kidney Dis 23:91-98, 1994
12. Spiegel DM, Breyer JA: Serum albumin: A predictor of long-term outcome in peritoneal dialysis patients. Am J Kidney Dis 23:283-285, 1994
13. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, Collins AJ: Trends in anemia at initiation of dialysis in the United States. Kidney Int 60:1875-1884, 2001
14. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
15. Lim VS, Fangman J, Flanigan MJ, DeGowin RL, Abels RT: Effect of recombinant human erythropoietin on renal function in humans. Kidney Int 37:131-136, 1990
16. Abraham PA, Opsahl JA, Rachael KM, Asinger R, Halstenson CE: Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 10:128-136, 1990
17. Clyne N, Jogestrand T: Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 60:390-396, 1992
18. Roth D, Smith RD, Schulman G, et al: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784, 1994
19. US Renal Data System: USRDS 1999 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 1999
20. Kaysen GA, Stevenson FT, Depner TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 29:658-668, 1997
21. Yeun JY, Kaysen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 32:S118-S125, 1998 (suppl 4)
22. Qureshi AR, Alvestrand A, Divino-Filho JC, et al: Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13:S28-S36, 2002 (suppl 1)
23. Silberberg J, Racine N, Barre P, Sniderman AD: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 6:1-4, 1990
24. Cannella G, La Canna G, Sandrini M, et al: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 6:31-37, 1991
25. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 35:280-287, 1991
26. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5:95-110, 1992
27. Fellner SK, Lang RM, Neumann A, Korcarz C, Borow KM: Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 44:1309-1315, 1993
28. Hayashi T, Suzuki A, Shoji T, et al: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256, 2000
29. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in endstage renal disease. Kidney Int 36:286-290, 1989
30. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
31. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541-548, 1997